ALPHA

EQS-News: NEON EQUITY AG with significant profit increase in the 2023 financial year

Retrieved on: 
Friday, May 3, 2024
Annual, NEON, Frankfurt, HGB, Tax, ALPHA, EQUITY, EUR, ESG, Health

Frankfurt am Main, April 24, 2024 - NEON EQUITY AG (NEON EQUITY, ISIN: DE000A3DW408), a founder-managed investor and growth enabler, publishes its audited key financial figures in accordance with HGB accounting.

Key Points: 
  • Frankfurt am Main, April 24, 2024 - NEON EQUITY AG (NEON EQUITY, ISIN: DE000A3DW408), a founder-managed investor and growth enabler, publishes its audited key financial figures in accordance with HGB accounting.
  • NEON EQUITY reported equity of around EUR 219.2 million as at December 31, 2023, compared to EUR 200.8 million a year earlier.
  • For example, NEON EQUITY invested in the innovative health tech company EasyMotionSkin Tec AG and the electric car manufacturer ELARIS AG.
  • The audited annual financial statements for 2023 are available on the NEON EQUITY website: https://craft-cms-assets.fra1.cdn.digitaloceanspaces.com/neonequity-webs...
    NEON EQUITY invites you to the Annual General Meeting on May 28, 2024.

Q1 2024 results

Retrieved on: 
Thursday, April 25, 2024
Oncology, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Annual general meeting, Annual, Osimertinib, LAURA, Dive (Belgian band), Lung cancer, PTEN, NMOSD, CER, FY, Blas, Outline, Budesonide, Total revenue, Growth, AstraZeneca, ASCO, EVH, Acquisition, EPS, PNH, ALPHA, NSCLC, Pharmaceutical industry

The increase in Core EPS was lower than Total Revenue growth principally due to a $241m gain in the prior year period on the disposal of Pulmicort Flexhaler US rights

Key Points: 
  • The increase in Core EPS was lower than Total Revenue growth principally due to a $241m gain in the prior year period on the disposal of Pulmicort Flexhaler US rights
    As announced at the Annual General Meeting on 11 April 2024, the total dividend for FY 2024 will increase by $0.20 per share to $3.10 per share
    "AstraZeneca had a very strong start in 2024 with substantial Total Revenue growth of 19% in the first quarter.
  • We are also looking forward to seeing the results of several other important trials throughout the year.
  • If foreign exchange rates for April 2024 to December 2024 were to remain at the average rates seen in March 2024, compared to the performance at CER it is anticipated that FY 2024 Total Revenue would incur a low single-digit adverse impact and Core EPS would incur a mid single-digit adverse impact (previously low single-digit).
  • AstraZeneca will host an Investor Day on 21 May 2024.

VOYDEYA™ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNH

Retrieved on: 
Monday, April 1, 2024
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Factor D, Arthralgia, Chest pain, Confusion, Neuropsychological test, Infection, Eculizumab, Risk, Headache, ALPHA, PNH, C5, Patient, Orphan, Mitigation, Vaccine, Light, Paroxysmal nocturnal hemoglobinuria, EVH, Bacteria, University, Chills, MD, Breakthrough therapy, Cough, European Medicines Agency, Fatigue, Nausea, Rash, Fever, Priority, Safety, Immune system, REMS, Division, Vomiting, Hematology, Patient safety, Medicine

VOYDEYA has also been granted Orphan Drug Designation in the US, European Union (EU) and Japan for the treatment of PNH.

Key Points: 
  • VOYDEYA has also been granted Orphan Drug Designation in the US, European Union (EU) and Japan for the treatment of PNH.
  • You must complete or update meningococcal vaccine(s) and streptococcus vaccine(s) at least 2 weeks before your first dose of VOYDEYA.
  • If you have been vaccinated against these bacteria in the past, you might need additional vaccinations before starting VOYDEYA.
  • Carry it with you at all times during treatment and for 1 week after your last VOYDEYA dose.

EQS-News: NEON EQUITY AG with leap in profits in 2023

Retrieved on: 
Thursday, February 15, 2024
Elaris, ALPHA, Initial public offering, Investment, TEC, Growth, NEON, EUR, HGB, Accounting, EQUITY, Tax, Frankfurt, Financial services

Frankfurt am Main, 15 February 2024 – NEON EQUITY AG (NEON EQUITY ISIN: DE000A3DW408), a founder-led investor and growth enabler, announces its preliminary, unaudited key financial figures for 2023 according to HGB accounting and was able to significantly increase its profit.

Key Points: 
  • Frankfurt am Main, 15 February 2024 – NEON EQUITY AG (NEON EQUITY ISIN: DE000A3DW408), a founder-led investor and growth enabler, announces its preliminary, unaudited key financial figures for 2023 according to HGB accounting and was able to significantly increase its profit.
  • NEON EQUITY was thus able to continue its profitable growth in the 2023 financial year.
  • NEON EQUITY has also supported numerous companies in their growth financing, for example the international nuclear fusion company ALPHA RING.
  • Thomas Olek, CEO and founder of NEON EQUITY: "2023 was a very important year for us.

POWER ALPHA 2.0: The First Ever Charge-Free 15,000+ Puffs Vape Solution by FEELM

Retrieved on: 
Wednesday, January 31, 2024
Multimedia, Taste, Herbal cigarette, Research, ALPHA, MESH, POWER, TPE, Rage, Electric battery

LAS VEGAS, Jan. 31, 2024 /PRNewswire/ -- 2024 January 31st, FEELM, a leading provider of closed-system vape solutions, released the world's first charge-free disposable technology solution for large-puffs, POWER ALPHA 2.0.

Key Points: 
  • LAS VEGAS, Jan. 31, 2024 /PRNewswire/ -- 2024 January 31st, FEELM, a leading provider of closed-system vape solutions, released the world's first charge-free disposable technology solution for large-puffs, POWER ALPHA 2.0.
  • Previous reports of the original POWER ALPHA technology can only support 6,000 puffs without charging.
  • This time, with the rapidly increasing in the number of puffs in disposable products, FEELM has once again taken the lead by launching POWER ALPHA 2.0, a charge-free disposable solution for more than 15,000 puffs.
  • Previously, in the European market, FEELM took the lead in launching the world's first ceramic core disposable solution, FEELM Max.

Laguna Tech USA Announces Site Record Number of Transcatheter Heart Valves Implanted at Single Center on Same Day in First-in-Human Clinical Trial

Retrieved on: 
Wednesday, January 3, 2024
Calcification, Fluoroscopy, University, Aortic regurgitation, Tricuspid valve, Calcium, ALPHA, Heart, Engineering, Aortic valve, Patient, Interventional cardiology, Medical device

All five implants were accomplished on the same day at the Instituto Nacional de Torax in Santiago, Chile within the ongoing feasibility trial for the ZETA system.

Key Points: 
  • All five implants were accomplished on the same day at the Instituto Nacional de Torax in Santiago, Chile within the ongoing feasibility trial for the ZETA system.
  • The ZETA system is a novel balloon-expandable transcatheter valve with six expanding arms and a low profile covered delivery system.
  • Additionally, by fluoroscopy, all implanted ZETA valves were consistently implanted within two millimeters of the annulus.
  • We look forward to scaling this technology and moving into later stage clinical development so we can bring this technology to a greater population of patients.”

Xcel Brands Announces License with ALPHA OES for Longaberger

Retrieved on: 
Monday, November 13, 2023
Social commerce, Acquisition, ALPHA, E-commerce, The Longaberger Company, Xcel Energy

NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Xcel Brands, Inc. (NASDAQ: XELB) (“Xcel” or the “Company”), a media and consumer products company with billions of dollars in retail sales generated by its brands through social commerce and live-stream shopping, today announced a new licensing agreement with ALPHA OES, a provider of eCommerce services and strategies for brands.

Key Points: 
  • NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Xcel Brands, Inc. (NASDAQ: XELB) (“Xcel” or the “Company”), a media and consumer products company with billions of dollars in retail sales generated by its brands through social commerce and live-stream shopping, today announced a new licensing agreement with ALPHA OES, a provider of eCommerce services and strategies for brands.
  • Under the terms of the licensing agreement, ALPHA OES will take over the day-to-day operations for Xcel’s Longaberger eCommerce business.
  • “We’re excited to partner with ALPHA OES on the Longaberger brand,” said Robert W. D’Loren, Chairman and CEO of Xcel Brands.
  • We’re also excited to work with Xcel on bringing Longaberger onto their social commerce marketplace, which we believe has the potential to reinvent customer acquisition of eCommerce brands that have a highly engaged audience through social commerce.”
    Under the new agreement, ALPHA OES will take over day-to-day management of Longaberger’s eCommerce business under a license with Longaberger Licensing, a subsidiary of Xcel.

EQS-News: NEON EQUITY AG supports international core fusion company ALPHA RING in growth financing

Retrieved on: 
Thursday, October 26, 2023
National university, EQUITY, National Taiwan University, ALPHA, Frankfurt, Autodesk, Research, NEON, Lithium

Frankfurt am Main, October 26, 2023 - NEON EQUITY AG (NEON EQUITY ISIN: DE000A3DW408), a founder-led investor and growth enabler, advises the internationally active energy technology company ALPHA RING on its growth financing and on creating increased awareness in Europe.

Key Points: 
  • Frankfurt am Main, October 26, 2023 - NEON EQUITY AG (NEON EQUITY ISIN: DE000A3DW408), a founder-led investor and growth enabler, advises the internationally active energy technology company ALPHA RING on its growth financing and on creating increased awareness in Europe.
  • NEON EQUITY will present ALPHA RING its international investor network with a focus on impact investing and establish corresponding contacts.
  • NEON EQUITY will benefit in particular from the technology know-how and expert network of the growth company.
  • Thomas Olek, CEO and founder of NEON EQUITY: "ALPHA RING fits perfectly into our profile for consulting and cooperation partners.

Laguna Tech USA Announces Newly Designed Heart Valves with Advanced Engineering Successfully Implanted in First-in-Human Clinical Trial

Retrieved on: 
Tuesday, October 24, 2023
University, Patient, Trial of the century, Interventional cardiology, Heart, Aortic valve, Instituto Nacional General José Miguel Carrera, ALPHA, Tricuspid valve, Engineering, Aortic regurgitation, ZETA, TAVI, Medical imaging, Medical device

New heart valves, ALPHA and ZETA, designed to provide flexibility and optionality regardless of high, low or zero calcification status

Key Points: 
  • New heart valves, ALPHA and ZETA, designed to provide flexibility and optionality regardless of high, low or zero calcification status
    Patients with aortic regurgitation achieve complete resolution of regurgitation immediately following procedure.
  • To date, two patients have been successfully treated in the Alpha Aortic Valve study, with both achieving complete resolution of aortic regurgitation immediately following the procedure, which has been maintained at the 30-day follow-up examination.
  • The ZETA system is a novel balloon-expandable transcatheter valve with six expanding arms and a low profile covered delivery system.
  • The feasibility study is being conducted at the Instituto Nacional de Torax in Santiago, Chile, and Tbilisi Heart and Vascular Clinic in Georgia.

Cyclohexanone Market Trends: Expanding Applications Propel Steady Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, October 9, 2023
Chemicals, Plastics, Manufacturing, Online, Food, Climate change, Developed country, Asahi Kasei, BASF, Machine learning, Corporation, Government, Adipic acid, GDP, AI, Report, BASF SE, SE, Growth, AdvanSix, Policy, ALPHA, Pet industry, Renewable energy, Video game, Caprolactam, CEPSA, Euro, Cyclohexanone

The global market for Cyclohexanone, estimated at US$7.5 billion in 2022, is on a growth trajectory, projected to attain a revised size of US$9.5 billion by 2030, with a steady CAGR of 3.1% over the analysis period spanning from 2022 to 2030.

Key Points: 
  • The global market for Cyclohexanone, estimated at US$7.5 billion in 2022, is on a growth trajectory, projected to attain a revised size of US$9.5 billion by 2030, with a steady CAGR of 3.1% over the analysis period spanning from 2022 to 2030.
  • U.S. Market Estimated at $527.1 Million, China Forecasted to Grow at 4.5% CAGR
    In the U.S., the Cyclohexanone market is estimated at US$527.1 million in 2022.
  • China is anticipated to experience robust GDP growth as the pandemic threat diminishes, and the government adjusts its policy stance.
  • Access to curated YouTube video transcripts featuring insights from CEOs, domain experts, and market influencers via interviews, podcasts, press statements, and event keynotes.